Patients with Parkinson's disease commonly experience non-motor sleep disturbances, including insomnia and circadian rhythm disruption. These comorbidities require systematic evaluation and targeted management as part of the overall care plan.
This protocol applies to patients with Parkinson's disease who also present with insomnia or a circadian rhythm disorder. Before initiating pharmacological treatment, underlying causes — including medication side effects and primary sleep disorders — should be systematically ruled out.
When sleep disturbance persists after addressing reversible causes, pharmacological sleep support may be considered. The protocol identifies specific agents targeting insomnia in this population — though evidence remains limited. Full selection criteria, sequencing, and agent-specific guidance are available in the complete protocol.
DOI: 10.1186/s42466-024-00325-4
In cases of insomnia or circadian rhythm disorders, underlying causes such as medication side effects and/or primary sleep disorders like SBAS should be ruled out.
Eszopiclone, Doxepin, Zolpidem, Trazodone, Melatonin, Venlafaxine (in comorbid depression), Nortriptyline, or Mirtazapine may be considered for insomnia despite weak evidence.
View source ↗